UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
Commission File Number |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders
On July 31, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), held its annual meeting of stockholders (the “Annual Meeting”) to vote on the following matters:
| 1. | Election of Directors. |
All of the following six nominees were elected to the Company’s board of directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.
| Nominee | For | Against | Withheld | Broker Non-Votes | ||||||||||||
| Anatoly Dritschilo, MD | 6,943,124 | - | 1,620,651 | 2,470,233 | ||||||||||||
| Milton Brown, MD, PhD | 6,944,980 | - | 1,618,795 | 2,470,233 | ||||||||||||
| Chris Senanayake, PhD | 7,123,328 | - | 1,440,447 | 2,470,233 | ||||||||||||
| Steven Richards | 7,124,051 | - | 1,439,724 | 2,470,233 | ||||||||||||
| Joshua Schafer | 7,126,327 | - | 1,437,448 | 2,470,233 | ||||||||||||
| Bette Jacobs, PhD | 7,124,105 | - | 1,439,670 | 2,470,233 | ||||||||||||
| 2. | Ratification of the Company’s Independent Auditors. |
Stockholders ratified the appointment of Forvis Mazars LLP as the Company’s independent auditors for the fiscal year ending December 31, 2024, in accordance with the voting results below.
| For | Against | Abstain | Broker Non-Votes | |||||||||||
| 9,357,834 | 427,437 | 1,248,737 | - | |||||||||||
| 3. | Approval of the Company’s Executive Compensation. |
Stockholders approved (on an advisory basis) the Company’s executive compensation.
| For | Against | Abstain | Broker Non-Votes | |||||||||||
| 6,453,985 | 990,915 | 1,118,875 | 2,470,233 | |||||||||||
| 4. | Approval of the authorization of the board of directors to amend the Company’s amended and restated certificate of incorporation to effect a reverse stock split of all of the Company’s issued and outstanding common stock by a ratio in the range of 1-for-3 to 1-for-8. |
Stockholders approved the authorization of the board of directors to amend the Company’s amended and restated certificate of incorporation to effect a reverse stock split of all of the Company’s issued and outstanding common stock by a ratio in the range of 1-for-3 to 1-for-8, in accordance with the voting results below.
| For | Against | Abstain | Broker Non-Votes | |||||||||||
| 8,253,951 | 2,488,770 | 291,287 | - | |||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: | August 1, 2024 | |
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | ||
| By: | /s/ Timothy J. Lorber | |
| Name: | Timothy J. Lorber | |
| Title: | Chief Financial Officer | |